ATE495754T1 - Verwendung eines nukleinsäuremoleküls kodierend für das disintegrin-domains eines adamalysins als anti-angiogenesis, anti-invasions und anti- metastasis mittel - Google Patents

Verwendung eines nukleinsäuremoleküls kodierend für das disintegrin-domains eines adamalysins als anti-angiogenesis, anti-invasions und anti- metastasis mittel

Info

Publication number
ATE495754T1
ATE495754T1 AT02774845T AT02774845T ATE495754T1 AT E495754 T1 ATE495754 T1 AT E495754T1 AT 02774845 T AT02774845 T AT 02774845T AT 02774845 T AT02774845 T AT 02774845T AT E495754 T1 ATE495754 T1 AT E495754T1
Authority
AT
Austria
Prior art keywords
tumor
operably linked
sequence
mammal
seq
Prior art date
Application number
AT02774845T
Other languages
English (en)
Inventor
Veronique Trochon
He Lu
Claudine Soria
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE495754T1 publication Critical patent/ATE495754T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02774845T 2001-07-26 2002-07-26 Verwendung eines nukleinsäuremoleküls kodierend für das disintegrin-domains eines adamalysins als anti-angiogenesis, anti-invasions und anti- metastasis mittel ATE495754T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110015A FR2827775B1 (fr) 2001-07-26 2001-07-26 Utilisation dans une composition anti-angiogenique du domaine disintegrine d'adamalysine
PCT/FR2002/002691 WO2003009866A1 (fr) 2001-07-26 2002-07-26 Utilisation du domaine disintegrine d'une adamalysine comme agent anti-angiogenique, anti-invasif et anti-metastatique

Publications (1)

Publication Number Publication Date
ATE495754T1 true ATE495754T1 (de) 2011-02-15

Family

ID=8865951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774845T ATE495754T1 (de) 2001-07-26 2002-07-26 Verwendung eines nukleinsäuremoleküls kodierend für das disintegrin-domains eines adamalysins als anti-angiogenesis, anti-invasions und anti- metastasis mittel

Country Status (14)

Country Link
US (2) US8207137B2 (de)
EP (1) EP1409008B1 (de)
JP (1) JP4332423B2 (de)
CN (1) CN1321689C (de)
AT (1) ATE495754T1 (de)
CA (1) CA2453561C (de)
CY (1) CY1111941T1 (de)
DE (1) DE60238986D1 (de)
DK (1) DK1409008T3 (de)
ES (1) ES2359394T3 (de)
FR (1) FR2827775B1 (de)
IL (2) IL159986A0 (de)
PT (1) PT1409008E (de)
WO (1) WO2003009866A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1759714A1 (de) * 2005-09-02 2007-03-07 Bioalliance Pharma Elektrotransfer von Nukleinsäuren in Gewebezellen
US20090220463A1 (en) * 2006-01-19 2009-09-03 Doo-Sik Kim Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide
US9101581B2 (en) 2008-10-27 2015-08-11 Eyegene Inc. Method for treating vascular-related disease
CN101379082A (zh) 2006-01-19 2009-03-04 爱吉恩公司 治疗血管相关疾病的包含肽的药物组合物
EP1970441A1 (de) * 2007-03-06 2008-09-17 BioAlliance Pharma Plasmid mit einer Sequenz, die eine Disintegrin-Domäne von Metargidin (RDD) kodiert
EP2353607A1 (de) 2010-02-04 2011-08-10 BioAlliance Pharma Verwendung einer Disintegrin-Domäne eines Adamalysins zur Behandlung von Psoriasis
EP2910565A3 (de) * 2010-02-11 2015-11-04 University of Southern California Modifizierte ADAM-Disintegrin-Domänen-Polypetide und Verwendungen
KR101338473B1 (ko) 2011-09-20 2013-12-10 연세대학교 산학협력단 미세소낭성 ａｄａｍ１５를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물
WO2021185719A1 (en) * 2020-03-15 2021-09-23 Ac Bioscience Sa Rgd-containing peptide and use thereof for cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814609A (en) * 1993-10-22 1998-09-29 University Of Southern California Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions
WO2000043493A2 (en) * 1999-01-22 2000-07-27 Human Genome Sciences, Inc. Metalloproteinase adam 22
AU5043200A (en) * 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
DE60127656T2 (de) * 2000-02-25 2007-12-20 Immunex Corp., Seattle Integrin antagonisten
EP1803810A1 (de) * 2000-02-25 2007-07-04 Immunex Corporation Integrinantagonisten
CA2399913A1 (en) * 2000-03-03 2001-09-13 Human Genome Sciences, Inc. Adam polynucleotides, polypeptides, and antibodies
US6294368B1 (en) * 2001-03-22 2001-09-25 Applera Corporation Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof

Also Published As

Publication number Publication date
FR2827775B1 (fr) 2003-09-26
IL159986A (en) 2011-01-31
JP4332423B2 (ja) 2009-09-16
CN1321689C (zh) 2007-06-20
CN1535156A (zh) 2004-10-06
CA2453561C (fr) 2013-03-12
PT1409008E (pt) 2011-04-18
CY1111941T1 (el) 2015-11-04
US20130158502A1 (en) 2013-06-20
WO2003009866A1 (fr) 2003-02-06
DK1409008T3 (da) 2011-05-16
FR2827775A1 (fr) 2003-01-31
US8207137B2 (en) 2012-06-26
EP1409008B1 (de) 2011-01-19
EP1409008A1 (de) 2004-04-21
JP2005502638A (ja) 2005-01-27
ES2359394T3 (es) 2011-05-23
IL159986A0 (en) 2004-06-20
DE60238986D1 (de) 2011-03-03
CA2453561A1 (fr) 2003-02-06
US20040171549A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
CY1111941T1 (el) Χρηση ενος μοριου νουκλεϊνικου οξεως το οποιο κωδικοποιει τον τομεα δισιντεγρινης μιας αδαμαλυσινης ως αντι-αγγειογονου, αντι-διεισδυτικου και αντι-μεταστατικου παραγοντα
Faye et al. The synthesis of antibacterial proteins in isolated fat body from Cecropia silkmoth pupae
WO2018104540A4 (en) Rnas for wound healing
ATE320815T1 (de) Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
EP0207751A1 (de) Fibronectine
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
IL190793A0 (en) A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
MXPA04003773A (es) Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.
ATE536745T1 (de) Zusammensetzung mit arazym zur prävention und behandlung von krebs
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
AP2000001999A0 (en) Gene therapy method.
Byrnes et al. Success and limitations of a naked plasmid transfection protocol for keratinocyte growth factor‐1 to enhance cutaneous wound healing
Mencı́a et al. Residues of the Bacillus subtilis phage φ29 transcriptional activator required both to interact with RNA polymerase and to activate transcription
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
EP0808899A3 (de) Menschlicher "Marco Scavenger" Rezeptor (HMarcoSR)
NZ504327A (en) Gene expressed in hypothalamus of obese animals and pharmaceutical use
WO1999012576A3 (en) Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
DE69738433D1 (de) Rezeptor-tyrosine-kinase gene
PT914417E (pt) Dnase ii humana
ATE455850T1 (de) Contortrostatin(cn) sowie verfahren zu seiner verwendung in der prävention von metastasen und anderer zustände

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1409008

Country of ref document: EP